Andrew Dunn is a biopharma correspondent, focused on uncovering and explaining the future of the biotech and pharmaceutical industries. He joined Endpoints News in 2023, most recently working as a senior healthcare reporter at Business Insider. He previously worked as a reporter at BioPharma Dive, and his reporting has been cited by news outlets including the Washington Post, CNN, and the New York Times. He’s also appeared on CNBC, C-SPAN, and MSNBC to discuss his work. He graduated from the University of Maryland, College Park, majoring in journalism and economics, and lives in Washington, DC.
Sign up for free to read a limited number of articles each month.About You
Pick what newsletters get delivered to your inbox each week.
Want unlimited access? Sign up for a premium subscription plan.
Join over 187,100 biopharma colleagues who rely on Endpoints News every business day for the latest developments in drug discovery, development, and commercialization.